- Open Access
Inhibition of glycolysis and mitochondrial respiration promotes radiosensitisation of neuroblastoma and glioma cells
Cancer & Metabolism volume 9, Article number: 24 (2021)
Neuroblastoma accounts for 7% of paediatric malignancies but is responsible for 15% of all childhood cancer deaths. Despite rigorous treatment involving chemotherapy, surgery, radiotherapy and immunotherapy, the 5-year overall survival rate of high-risk disease remains < 40%, highlighting the need for improved therapy. Since neuroblastoma cells exhibit aberrant metabolism, we determined whether their sensitivity to radiotherapy could be enhanced by drugs affecting cancer cell metabolism.
Using a panel of neuroblastoma and glioma cells, we determined the radiosensitising effects of inhibitors of glycolysis (2-DG) and mitochondrial function (metformin). Mechanisms underlying radiosensitisation were determined by metabolomic and bioenergetic profiling, flow cytometry and live cell imaging and by evaluating different treatment schedules.
The radiosensitising effects of 2-DG were greatly enhanced by combination with the antidiabetic biguanide, metformin. Metabolomic analysis and cellular bioenergetic profiling revealed this combination to elicit severe disruption of key glycolytic and mitochondrial metabolites, causing significant reductions in ATP generation and enhancing radiosensitivity. Combination treatment induced G2/M arrest that persisted for at least 24 h post-irradiation, promoting apoptotic cell death in a large proportion of cells.
Our findings demonstrate that the radiosensitising effect of 2-DG was significantly enhanced by its combination with metformin. This clearly demonstrates that dual metabolic targeting has potential to improve clinical outcomes in children with high-risk neuroblastoma by overcoming radioresistance.
Neuroblastoma comprises 7% of paediatric malignancies but has a worse prognosis than many other tumour types, accounting for approximately 15% of childhood cancer deaths . Age at diagnosis, along with stage and molecular characteristics of the tumour, is used to allocate patients to low-intermediate- or high-risk groups. Younger age, low stage, and absence of segmental chromosomal abnormalities or oncogenic MYCN amplification are favourable features. However, most patients have high-risk disease by virtue of age greater than 12 months and distant metastatic disease or MYCN amplification . The standard treatment schedule for high-risk neuroblastoma involves a complex multimodality schedule comprising induction chemotherapy , surgery , high-dose chemotherapy , radiotherapy  and immunotherapy . While some patients respond well, some are refractory to initial treatments or relapse later. As neuroblastoma arises from primordial neural crest cells, most commonly in the adrenal medulla and also at other sites in the sympathetic nervous system, neuroblastoma cells usually retain the ability to take up catecholamines and analogues such as meta-iodobenzylguanidine (MIBG) . Imaging with 123I-MIBG is used for staging and response assessment, and 131I-MIBG is a valuable treatment option .
The prognosis for patients with high-risk neuroblastoma has undoubtedly improved significantly over recent decades due to international cooperative group phase III trials investigating intensification of treatments such as high-dose chemotherapy and immunotherapy. Different sources yield different survival rates depending on the era of presentation, clinical trial selection factors, treatments used, and follow-up duration. Ten-year overall survival rates remain in the order of only 40% [10, 11], and while newer approaches offer the prospect of improvements in long-term survival, follow-up durations are currently insufficient to confirm these hopes . Although 131I-MIBG is useful in the treatment of refractory and relapsed high-risk neuroblastoma and is the subject of clinical trials (ClinicalTrials.gov identifiers NCT02035137 and NCT03165292) aiming to optimise its use, further strategies are required to ensure that maximal benefit is obtained [13, 14]. It is likely that maximal therapeutic benefit from targeted radiotherapy will be obtained by its combination with drugs , which might render it more effective specifically for high-risk neuroblastoma patients, who do not benefit from existing therapies.
In recent years, a growing body of evidence has emerged demonstrating the anticancer properties of drugs that modulate cellular metabolism. Aberrant mitochondrial metabolism is a common trait among cancers. This is exemplified by the Warburg effect, which is characterised by increased rates of glycolysis and lactate production, even in the presence of oxygen . Dysregulated cancer cell metabolism has been linked to increased tumour aggressiveness and treatment resistance . Indeed, targeting glucose metabolism has yielded chemo- and radiosensitisation in several cancer types [17, 18]. Of relevance to this study, neuroblastoma cells have been reported to exhibit aberrant metabolic properties, including increased fatty acid synthase expression  and altered fatty acid and glucose metabolism .
The synthetic glucose analogue 2-deoxyglucose (2-DG) is avidly taken up by rapidly proliferating cells, including cancer cells. Once internalised, 2-DG is unable to undergo isomerisation at its second carbon atom to produce 2-deoxyglucose-6-phosphate, a phenomenon that leads to inhibition of glycolysis at the phosphoglucoisomerase level. Therefore, treatment with 2-DG becomes cytotoxic in the contexts of ATP depletion  or disruption of glutathione metabolism . In keeping with this, 2-DG was shown to be an effective radiosensitiser of HeLa cells  and was well tolerated in combination with docetaxel in a phase 1, dose-escalation clinical trial .
Metformin is a biguanide drug that is widely prescribed for the treatment of type 2 diabetes, acting to reduce insulin resistance, enhance glucose utilisation and reduce hepatic glucose production . At the cellular level, metformin promotes AMPK activation during energy homeostasis via inhibition of Complex I of the mitochondrial respiratory chain [25, 26]. Indeed, metformin has been shown to exhibit antineoplastic activity in the context of exogenously induced changes in energy homeostasis . Additionally, patients with type 2 diabetes who were receiving metformin as part of their diabetic management have been shown to experience reduced incidence and better survival rates for many solid cancers [28,29,30].
In keeping with these observations, both 2-DG and metformin have shown potential as radio- [22, 31,32,33,34] and chemosensitisers [23, 35, 36]. However, their ability to sensitise neuroblastoma cells to radiotherapy has not yet been studied, and the mechanisms underlying their radiosensitising properties are poorly understood. Accordingly, we investigated the potential of 2-DG and metformin to enhance the efficacy of X-irradiation in pre-clinical models of neuroblastoma. We show that 2-DG effectively radiosensitises neuroblastoma and glioma cells, effects that are significantly enhanced in the presence of metformin, and demonstrate that combining 2-DG, metformin and radiation induces extensive metabolic reprogramming. This is characterised by reduced cellular respiration and ATP production that associates with prolonged G2/M arrest during which cells ultimately succumb to apoptotic cell death. Our results indicate that dual pharmacological inhibition of glycolysis and mitochondrial respiration has potential to enhance the efficacy of radiation therapy in patients with neuroblastoma.
Materials and methods
2-Deoxy-D-glucose (2DG; D3179) and metformin hydrochloride (PHR1084) were purchased from Sigma-Aldrich (Poole, UK) and were reconstituted using sterile water. Drugs were then diluted in culture medium. Unless otherwise stated, all other cell culture reagents were purchased from Thermo Fisher Scientific (Paisley, UK) and all chemicals were purchased from Sigma-Aldrich (Poole, UK).
Human neuroblastoma SK-N-BE(2c) cells were purchased from the American Type Culture Collection and were maintained in Dulbecco’s modified Eagle medium (DMEM) containing 15% (v/v) fetal calf serum, 2 mM L-glutamine and 1% (v/v) non-essential amino acids. Human glioblastoma UVW cells were transfected with a plasmid containing the bovine noradrenaline transporter (NAT) gene  and were maintained in minimum essential medium (MEM) containing 10% (v/v) fetal calf serum, 2 mM L-glutamine, 1% (v/v) non-essential amino acids and 1 mg/ml geneticin. Human neuroblastoma CHLA-20 cells were obtained from the Children’s Oncology Group Childhood Cancer Repository (TX, USA) and were maintained in Iscove’s modified Dulbecco’s medium (IMDM) containing 20% (v/v) fetal calf serum, 2 mM L-glutamine and 1% (v/v) insulin-transferrin-selenium. All cells were incubated at 37 °C, 5% CO2 in a humidified incubator, and were passaged every 3–4 days. Cell lines were cultured in this study for less than 6 months after resuscitation and were deemed free of Mycoplasma contamination by in-house testing using the MycoAlert mycoplasma detection kit (Lonza, Bazel, Switzerland).
MTT cell growth assay
The MTT reduction assay was used to estimate the effect of drug treatment on cell growth up to 96 h post treatment. After seeding cells in 96-well plates, the following day, cells were washed with PBS before adding 200 μl drug-containing medium. After 24 h, 48 h, 72 h, and 96 h, cells were incubated for 2 h with 20 μl MTT solution (5 mg/ml MTT in PBS). Internalised MTT was solubilised with DMSO and absorbance was measured at 570 nm.
Monolayers were cultured in 25 cm2 flasks before 24-h drug treatment and simultaneous irradiation (Xstrahl RS225 X-Ray irradiator, Xstrahl Limited, Surrey, UK; dose rate of 0.93 Gy/min) at the stated concentrations and doses. Irradiation was always administered at the beginning of drug treatment, with the only exception being during the alternative scheduling experiments (as further detailed in the text). Clonogenic survival was determined by seeding 500 (SK-N-BE(2c)) or 250 (UVW/NAT) cells in to 21.5 cm2 petri dishes as previously described .
Spheroid growth delay
Cells were cultured in 25 cm2 flasks coated with 1% (w/v) agar to initiate multicellular spheroid formation. After 3 days, spheroids were transferred to sterile universal tubes before treatment in serum-free drug-containing medium and simultaneous irradiation. Spheroids were treated for 24 h, and those of approximately 100 μm in diameter were individually transferred to agar-coated 24-well plates, with 12 replicate spheroids per condition, as previously described [39, 40]. Each spheroid was imaged every 3–4 days for 3 weeks using an inverted phase contrast microscope. The longest spheroid length, dmax, and its perpendicular width, dmin, were measured using ImageJ (NIH, Bethesda, MD). Tumour volume, V (μm3) was then estimated assuming V = π × dmax × dmin2/6 , which allowed determination of the area under the V/V0 versus time curve (AUC) using trapezoidal approximation [39, 40].
Untargeted metabolomic analysis
Hydrophilic interaction liquid chromatography (HILIC) was carried out on a Dionex UltiMate 3000 RSLC system (Thermo Fisher Scientific, Hemel Hempstead, UK) using a ZIC-pHILIC column (150 mm × 4.6 mm, 5-μm column, Merck Sequant). The column was maintained at 30 °C and samples were eluted with a linear gradient (20 mM ammonium carbonate in water and acetonitrile) over 26 min at a flow rate of 0.3 ml/min. The injection volume was 10 μl and samples were maintained at 5 °C prior to injection. Metabolites were detected using the Thermo Orbitrap Q Exactive (Thermo Fisher Scientific) mass spectrometer at a resolution of 70,000 (at 70–1050 m/z), which was operated in polarity switching mode. A pooled sample comprising a mixture of all sample extracts was analysed using the same conditions and was run every 5th sample. Instrument .raw files were converted to positive and negative ionisation mode mzXML files. These files were then analysed using the XCMS /MZMatch /IDEOM pipeline. Polyomics integrated Metabolomics Pipeline (PiMP) and FrAnK were used to assess fragmentation data . The weighted distance of treatment conditions to untreated control samples was calculated using the following equation:
where PC1repn is the PC1 value of each replicate and PC1Ctrlmean is the mean PC1 value of all untreated control samples . All metabolomic data has been uploaded to the repository MetaboLights (https://www.ebi.ac.uk/metabolights/).
Bioenergetic analysis of glycolysis and mitochondrial respiration
UVW/NAT cells and CHLA-20 cells were seeded at a density of 1 × 104 and 3 × 104 cells, respectively, in a volume of 175 μl in Seahorse XFe96-well plates (Cat# 101085-004, Seahorse Biosciences, Agilent Technologies, Cheshire, UK). Cells were allowed to settle for 2 h at room temperature, before drug treatment (25 μl) and simultaneous irradiation, as required. Mitochondrial respiration was measured 24 h after treatment using the Seahorse XFe96 Analyzer (Seahorse Biosciences, Agilent Technologies, Cheshire, UK) according to manufacturer’s instructions. On the day of the assay, culture medium was replaced with Seahorse XF base medium (Cat# 102353-100), supplemented with the regents required for each cell line (except FBS), as detailed above. Cells were then incubated for 1 h at 37 °C in the absence of CO2. Using the Seahorse Cell Mito Stress Test (Cat# 103015-100), sequential injections were made of oligomycin (1 μM), carbonyl cyanide-p-trifluoromethoxy-phenylhydrazone (FCCP) (1 μM), rotenone (0.5 μM) and antimycin A (0.5 μM) to test cellular response to mitochondrial stress in live cells. Mitochondrial oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were measured every 3 min, for a total of 75 min. The OCR and ECAR traces were then used to estimate basal and maximal respiration, ATP synthesis, and glycolytic rate as described previously . Data were normalised to protein content, which was determined after each Seahorse assay using the Pierce Micro BCA Protein Assay kit (Cat# 23235, Thermo Fisher Scientific, Paisley, UK), following manufacturer’s instructions.
Fluorescence-activated cell sorting (FACS) analysis
Cells were seeded at a density of 7 × 105 (SK-N-BE(2c)) or 4 × 105 (UVW/NAT) cells in 75 cm2 flasks. Drug-containing medium was added once cells were 60% confluent, and cells were simultaneously irradiated. After 24 h, cells were trypsinised and washed with PBS, before fixing with 70% (v/v) ethanol in water at − 20°C for a minimum of 6 h. Ethanol was removed by washing with PBS and cells were resuspended in PBS containing propidium iodide (10 μg/ml) and RNase A (200 μg/ml), before analysis using a BD FACSVerse flow cytometer (BD BioSciences, Oxford, UK). FACS data were quantified using FlowJo 7.6.5 software. Our gating strategy is provided in Supplementary Information Fig. S8a.
Live cell imaging
For real-time analysis of cellular proliferation and apoptotic frequency, UVW/NAT and CHLA20 cells were seeded in 96-well plates at densities of 1.5 × 103 or 1.75 × 104 cells/well, respectively. After overnight incubation at 37 °C, Annexin V-labelled cells (IncuCyte Annexin V Red, Cat# 4641, Essen BioScience, 1:400) were analysed with the IncuCyte ZOOM live cell imaging system (Essen BioScience, Hertfordshire, UK) following drug treatment (as detailed in the text). Each condition was replicated in six wells per experiment for each cell line. Two images per well were acquired every hour at a magnification of × 10, over a time period of 50 h. The number of Annexin V-positive cells was normalised to total cell confluence, using the IncuCyte ZOOM 2018A software (Ann Arbor, MI, USA).
Radiosensitising effect of 2DG and metformin as single agents
Both 2-DG and metformin exhibited modest activity as single agents, with reductions in cell proliferation and clonogenic survival being observed after exposure to concentrations greater than 1 mM 2DG or 10 mM metformin (Supplementary Information Fig. S1a-d). When delivered for 24 h commencing at the time of external beam radiation, 2-DG reduced the clonogenic capacity of UVW/NAT cells in a dose-dependent manner, with statistically significant radiosensitisation observed at 5 mM and 10 mM, with dose enhancement factors at 50% cell kill (DER50) of 1.80 and 1.69, respectively (Fig. 1a). Similarly, 10 mM 2-DG significantly enhanced X-irradiation induced growth delay in SK-N-BE(2c)-derived spheroids, with the combined effect being greater than either agent administered alone (Fig. 1b). In contrast, metformin had negligible effect on clonogenic survival of UVW/NAT cells when administered in combination with irradiation (Fig. 1c), results that were confirmed in SK-N-BE(2c) cells (Supplementary Information Fig. S2).
Combined effects of 2-DG and metformin on radiosensitisation
The failure of metformin to radiosensitise neuroblastoma and glioma cells contrasts with data from previous studies on pancreatic  and breast cancer cells . However, there is a rationale for combining metformin treatment with 2-DG treatment. Inhibition of glycolysis by 2-DG is predicted to cause a compensatory increase in mitochondrial respiration to maintain ATP production. Combination treatment with metformin would circumvent this compensatory increase in mitochondrial metabolism by inhibiting Complex 1 of the respiratory chain. There is also evidence of supra-additive activity of 2-DG and metformin combination treatment in other cancer types [47,48,49]. Most pertinently, Chatterjee and colleagues demonstrated that simultaneous administration of 2-DG and metformin enhanced radiation-induced cytotoxicity in two breast cancer cell lines .
In keeping with this rationale, 2-DG and metformin exerted additive effects on clonogenic cell kill in the absence of radiation (Supplementary Information Fig. S1e-f). Likewise, dual treatment with low doses of 2-DG and metformin (1 mM) significantly radiosensitised UVW/NAT cells (drugs administered for 24 h commencing at the time of irradiation, Fig. 2a) but failed to radiosensitise SK-N-BE(2c) cells (Fig. 2b).
Since SK-N-BE(2c) cells exhibit a longer population doubling time (37 h) than UVW/NAT cells (16 h), we postulated that more prolonged drug treatment might be required to radiosensitise these cells. However, 48h exposure to metformin and 2-DG also failed to increase radiation-induced cell kill (Fig. 2b).
Because of the discrepancy between UVW/NAT glioma cells and SK-N-BE(2c) neuroblastoma cells, we evaluated an alternative human neuroblastoma cell line, CHLA-20. These cells were unable to form the colonies required for clonogenic assay but readily formed three-dimensional spheroids. In this clinically relevant model, we observed enhanced spheroid growth delay following triple combination therapy, as opposed to single agent modalities (Fig. 2c).
Combination treatment significantly disrupts glycolysis, mitochondrial respiration and nucleotide metabolism
To understand why metformin enhanced the radiosensitising potential of 2-DG in UVW/NAT cells, we interrogated the effect of single agent and combination treatments on glycolytic and mitochondrial respiration metabolites. An initial untargeted analysis using a principal component plot revealed that 2-DG induced significant changes in the metabolomic composition of UVW/NAT cells, whether administered as a single agent or in combination (Fig. 3a). Further interrogation of glycolytic pathway metabolites revealed 2-deoxyglucose phosphate to be significantly increased in cells exposed to 2-DG treatment, proving that 2-DG was internalised and phosphorylated by hexokinase (Fig. 3b). This phosphorylation rendered 2-DG refractory to metabolism by glycolysis, as shown by the reduction in glyceradehyde-3-phosphate, phosphoenolpyruvate and pyruvate, the end-product of glycolysis, in all treatments involving 2-DG (Fig. 3b and Supplementary Information Fig. S3a).
Likewise, investigation of the tricarboxylic acid (TCA) cycle (Supplementary Information Fig. S3c) revealed citrate/isocitrate and malate to be significantly reduced following exposure to single agent or combination therapy involving 2-DG (Fig. 3c). Single agent metformin treatment also significantly reduced the relative abundancies of these metabolites, demonstrating inhibition of Complex 1 of the respiratory chain.
Our metabolomic analysis also revealed that 2-DG single agent treatment promoted large-scale changes in purine and pyrimidine metabolism. Specifically, we observed a decreased abundance in 20 of 26 metabolites detectable within the purine metabolic pathway (Supplementary Information Fig. S4). Similarly, 2-DG promoted a reduction in 11 of the 27 metabolites we detected within the pyrimidine metabolic pathway (Supplementary Information Fig. S5). Comparable results were observed after metformin single agent therapy, but to a lesser extent (data not shown). Further analysis of combination treatments revealed that dual 2-DG/metformin and triple 2-DG/metformin/radiation combination therapies significantly increased the abundance of ethanolamine phosphate and hypoxanthine (Fig. 3d; p < 0.001), which are products of serine and adenine metabolism, respectively. Interestingly, the increased abundance of these two metabolites was only observed following combination treatments.
Metabolite imbalance following therapeutic intervention culminates in impaired cellular respiration
Having demonstrated marked disruption of glycolysis and mitochondrial metabolism by our combination drug treatment, we explored its effects on cellular respiration and energy production. The mitochondrial respiratory profile of UVW/NAT and CHLA-20 cells was analysed using the Seahorse XF system, whereby live cells were sequentially injected with different test compounds to induce mitochondrial stress (Supplementary Fig. S6).
Initially, basal extracellular acidification rate (ECAR) was plotted against mitochondrial oxygen consumption rate (OCR) (Fig. 4a). While these bioenergetic profiles were unaffected by irradiation (3 Gy), 2-DG treatment promoted aerobic respiration, presumably in response to glycolytic inhibition, whereas metformin-treated cells became increasingly glycolytic as mitochondrial respiration was inhibited (Fig. 4a, b). The greatest shift in bioenergetics was seen following combination therapy involving 2-DG and metformin in the presence or absence of radiation, with cells becoming less energetic and more quiescent as the two central ATP production pathways were inhibited. Interestingly, single agent metformin produced the greatest shift in mitochondrial respiratory capacity, with no additional effect observed when 2-DG or radiation were added (Fig. 4c). Single agent 2-DG treatment, however, significantly increased both the respiratory capacity and ATP production of UVW/NAT cells. Our hypothesis that this reflected increased utilisation of more efficient mitochondrial ATP production was supported by the reversal of the effect that was observed when metformin was added (with or without irradiation, Fig. 4c, d). Comparably, combination treatment significantly reduced abundance of the metabolites AMP, ADP and ATP (Supplementary Information Fig. S3d). Similar results were obtained in CHLA-20 cells (Supplementary Fig. 7).
Taken together, these results demonstrate that 2-DG and metformin treatment caused significant disruption of glycolysis and/or the mitochondrial TCA cycle, which culminated in significantly impaired cellular energy production. However, this effect was not enhanced in the presence of irradiation, even though both drugs were required to enhance radiosensitivity.
Triple combination therapy significantly prolongs G2/M cell cycle arrest
To further understand the mechanisms underlying the efficacy of triple combination therapy, effects on cell cycle progression were investigated using the gating strategy presented in Supplementary Fig. S8a. Single agent 2-DG treatment at doses of 2.5 mM and above caused accumulation of cells in G2/M phase of the cell cycle after 6 h, whereas metformin had negligible effect on the proportion of G2/M phase cells at any dose (Supplementary Fig. S8b-c). However, combined low-dose (1 mM) treatment with 2-DG and metformin caused a marked G2/M arrest that was observed 6 h after treatment and failed to resolve at 24 h (Fig. 5a). Radiation alone (3 Gy) caused a temporary G2/M arrest, as expected, but did not amplify cell cycle effects of the drug combination (Fig. 5a).
Our previous studies have demonstrated the importance of scheduling when combining treatment modalities [39, 51], and we predicted that accumulation of cells in G2/M phase of the cell cycle would increase radiosensitivity  by doubling the amount of DNA susceptible to radiation damage in each cell. To investigate this possibility, three different schedules were tested: (1) three treatments simultaneously, (2) 2-DG and metformin 6 h prior to irradiation, and (3) irradiation 6 h prior to 2-DG and metformin (Supplementary Fig. S8d). Cells were harvested after a total treatment time of 24 h and analysed by propidium iodide staining and flow cytometry (Fig. 5b) or clonogenic assay (Fig. 5c), to determine effects on cell cycle distribution and cell survival, respectively. The 6h interval was selected because maximum G2/M arrest was observed at this timepoint (Fig. 5a) .
Maximum G2/M arrest at 24 h was observed when cells were irradiated 6 h prior to drug therapy (Schedule 3, Fig. 5b). Schedules 1 and 2 were less effective, yielding 2-fold increases in the proportion of cells in G2/M phase. While all three combination schedules enhanced clonogenic cell kill compared to individual treatments (Fig. 5c), no difference in efficacy was observed between the different schedules. These results demonstrate that increased G2/M arrest does not necessarily translate into increased clonogenic cell kill for this combination.
Sustained G2/M arrest promotes apoptotic cell death
To interrogate the possibility that prolonged G2/M arrest following triple combination therapy would culminate in apoptotic cell death, we used IncuCyte live cell imaging to determine the proportion of cells expressing the apoptotic marker Annexin V at multiple timepoints after treatments. These data showed that 2-DG but not metformin caused modest levels of apoptotic cell death as a single agent, with dual drug therapy showing a supra-additive effect in UVW/NAT cells (Fig. 6a, c). Radiation alone induced moderate apoptosis at early timepoints but did not further enhance efficacy of the 2-DG/metformin combination (Fig. 6b, c). Similar results were observed using CHLA-20 cells (Supplementary Fig. S9).
Despite rigorous multi-modal treatment regimens involving surgical resection, chemotherapy, radiotherapy and immunotherapy, high-risk neuroblastoma patients have 10-year overall survival rates of less than 40% [10, 11]. Targeted radiotherapy remains one of the most effective treatment options for high-risk disease , but most patients are not cured and so there is scope to improve its efficacy by using targeted drugs to overcome treatment resistance .
In this study we aimed to enhance radiosensitivity by inhibiting glycolysis, which is upregulated in cancer cells, thus disrupting the ATP generation required to fuel their rapid proliferation. Anticipating a compensatory increase in mitochondrial metabolism to maintain ATP production, we hypothesised that this could be circumvented by adding the mitochondrial respiratory chain inhibitor metformin. Building on recent observations in breast cancer cells , we tested these hypotheses by measuring the effects of 2-DG and metformin on the radiation responses of neuroblastoma and glioma cells.
Metformin failed to radiosensitise neuroblastoma (SK-N-BE(2c)) or glioma (UVW/NAT) cells when administered as a single agent, which is contrary to previous reports [31, 32, 34]. However, we did observe that low-dose 2-DG and metformin given in combination significantly increased the radiosensitivity of UVW/NAT cells but had negligible effects on SK-N-BE(2c) neuroblastoma cells, even when treatment was extended to 48 h. These observations are consistent with previous reports demonstrating a range of sensitivities to 2-DG and metformin combination treatment across cell lines [47,48,49]. Variability in response to metformin has been attributed to genetic characteristics including p53 deficiency [47, 48], AMPKα expression  and MYC status [49, 54].
Resistance of SK-N-BE(2c) cells to the 2-DG/metformin combination is likely to be explained by their genetic background, which includes p53 mutations  and amplification of the MYCN gene . Amplification of the neuronal transcription factor MYCN induces malignant transformation of neuroblastoma cells and is used for disease stratification , and sensitivity of neuroblastoma cells to impaired polyamine metabolism has been demonstrated to correlate with extent of MYCN amplification . We therefore extended our study to include CHLA-20 human neuroblastoma cells, which are non-MYCN amplified. Since CHLA-20 cells were unable to form clonogenic colonies, spheroid growth delay was used as a clinically relevant readout of radiosensitivity. In this cell line, dual treatment with 2-DG and metformin produced significantly greater radiosensitisation than either agent administered alone, supporting our findings in UVW/NAT cells and consistent with data derived from breast cancer [48, 50], prostate cancer  and paediatric glioma cells . Our findings support a potential role for MYCN amplification in treatment resistance of neuroblastoma cells that merits further investigation.
Interrogation of the cellular metabolome by mass spectrometric analysis demonstrated significant disruption of the glycolytic pathway and the electron transport chain (ETC) following exposure to 2-DG and metformin as single agents. We further showed that the greatest metabolite imbalance was observed following combination of 2-DG and metformin treatments. Even though this imbalance was not further exacerbated by irradiation, it set the scene for enhanced radiosensitivity. Further investigations revealed that these large-scale metabolic imbalances ultimately culminated in reduced cellular energy production. These results were corroborated by real-time analysis of oxygen consumption rate using the Seahorse system, wherein triple combination therapy produced a substantial shift in bioenergetic profile from a highly energetic to a largely quiescent cellular phenotype. Additionally, we observed significantly reduced ATP production, glycolytic rate, and respiratory capacity following exposure to combination treatments. Similar analysis of biogenetic profiles proved useful during the characterisation of different histological subtypes of ovarian cancer, in which highly glycolytic cell subtypes exhibited greater susceptibility to 2-DG . A key question is how do the metabolic imbalances detailed in this study relate to cell death following radiotherapy? Our data support a model in which (1) metabolic shifts from a highly energetic state to cellular quiescence prevent proliferation and (2) increased reliance on mitochondrial energy production following glycolytic inhibition increases production of reactive oxygen species (ROS), which enhances radiation-induced ROS production, thus increasing cytotoxicity. We hypothesise that inhibition of glycolysis by 2-DG causes a metabolic shift to oxidative phosphorylation (OXPHOS) in order to sustain ATP production, a compensatory mechanism that can be circumvented by adding metformin. Albeit by alternative methodologies, several other studies have also demonstrated reduced ATP content as a possible mechanism of additivity when 2-DG is combined with metformin [47, 49, 50].
Of course, the radiosensitising effect of 2-DG may not be solely due to inhibition of glycolysis. 2-DG is known to exert off-target affects as a mannose mimetic and can cause post-translational modifications such as N-linked glycosylation . Indeed, N-linked glycosylation, in which an oligosaccharide is attached to a protein residue via its nitrogen atom, is a post-translational event analogous to poly(ADP-ribosyl)ation, whereby ADP-ribose moieties are attached to a target protein at the site of DNA damage. We have previously demonstrated the radiosensitising properties of the poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors olaparib and rucaparib in neuroblastoma and glioma cells, where they act principally by preventing repair of radiation-induced damage . Indeed, this radiation-induced poly-(ADP-ribosyl)ation which would consume pools of NAD+ and ADP, would occur synonymously with the ATP depletion following combined 2-DG/metformin treatment. Presumably, AMP supplies would be depleted in attempts to replenish ADP/ATP levels. This may be a possible explanation as to why we observed significant reductions in abundance of AMP, ADP, ATP and NAD+ following combination therapy.
In addition to its well-documented effects on glucose metabolism, we also demonstrated that 2-DG treatment had significant effects on purine and pyrimidine metabolism. Of note were the changes observed in ethanolamine phosphate and hypoxanthine, which are generated by carboxylation of serine and deamination of adenine, respectively. These metabolites were significantly increased by dual and triple combination therapies, but not by single agent treatments. Their increased abundance may reflect attempts to repair radiation-induced DNA damage, which require cells to increase de novo purine and pyrimidine synthesis, with input from serine and adenine, to synthesise the nucleotides required for DNA repair. Indeed, nucleotide metabolism has been implicated in oncogene-induced cellular senescence due to the roles of nucleotides in replication stress and the DNA damage response .
Flow cytometric analysis revealed that although 2-DG and metformin, as single agents, induced modest accumulation of cells in the G2/M phase of the cell cycle, maximum G2/M arrest was achieved by combining the two agents, as previously shown by others [47, 48]. Our data also demonstrated that this G2/M arrest could be further enhanced by combination with X-irradiation and, more importantly, that it persisted for at least 24 h after irradiation. This indicated that optimal scheduling of therapeutic modalities could maximise arrest in G2/M — the most radiosensitive phase of the cell cycle. Indeed, we went on to show that scheduling X-irradiation exposure 6 h before 2-DG/metformin treatment maximised G2/M arrest. However, this treatment schedule did not further enhance clonogenic cell kill compared to the other two schedules, which is why simultaneous combinations were used for the rest of the study. We predicted that the mechanism by which the 2-DG/metformin combination increased radiosensitivity entailed induction of apoptosis during prolonged G2/M accumulation of cells, as shown previously [47, 49, 50]. This hypothesis was supported by our Incucyte data which showed the frequency of Annexin V-stained UVW/NAT and CHLA-20 cells to be significantly enhanced following 2-DG/metformin treatment, compared to single agent administration.
Like most other in vitro studies investigating this drug combination [47,48,49,50], we observed cytotoxic activity of 2-DG and metformin only at higher drug concentrations than could be achieved clinically. In contrast, we observed potent radiosensitising effects of the combination with lower concentrations (1 mM). Clinically, the recommended dose of 2-DG is 63 mg/kg/day (75 μM1), which achieved maximum plasma concentrations in the region of 116 μg/ml (0.7 μM) , although higher doses may be tolerated in combination with radiation therapy. And while metformin is not usually given to diabetic patients at doses higher than 1500–2000 mg/day, which deliver plasma concentrations of 22-29 μMFootnote 1 , it should be noted that shorter treatment regimens would be required in combination with radiotherapy, so it may be feasible to treat neuroblastoma patients with higher daily doses. Since both drugs are already clinically approved, exhibit favourable toxicity profiles and, as far as the authors are aware, have no documented maximum tolerated dose to date, we consider them to be promising therapeutic agents in combination with radiation therapy in paediatric patients.
In summary, we show for the first time that the glycolytic inhibitor 2-DG enhances the radiosensitivity of human neuroblastoma and glioma cells in vitro. The radiosensitising effects of 2-DG were greatly enhanced by combination with the antidiabetic biguanide, metformin. Metabolomic analysis revealed this combination to elicit severe disruption of key glycolytic and mitochondrial metabolites, causing significant reductions in ATP generation. These results were supported by cellular bioenergetic profiling. Combination treatment induced G2/M arrest that persisted for at least 24 h post-irradiation, promoting apoptotic cell death in a significant proportion of cells. Our findings suggest that targeting cellular metabolism has potential to improve clinical outcomes by overcoming radioresistance in children with high-risk neuroblastoma.
Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.
Assuming 80 kg average weight and 5.15 L average circulating blood volume.
Area under the curve
- DEF50 :
Dose enhancement factor observed at the 50% kill level
Dulbecco’s modified Eagle medium
Extracellular acidification rate
Hydrophilic interaction liquid chromatography
- IC50 :
50% Inhibitory concentration
Oxygen consumption rate
Polyomics integrated Metabolomics Pipeline
Gains J, Mandeville H, Cork N, Brock P, Gaze M. Ten challenges in the management of neuroblastoma. Future Oncol. 2012;8(7):839–58. https://doi.org/10.2217/fon.12.70.
Matthay KK, Maris JM, Schleiermacher G, Nakagawara A, Mackall CL, Diller L, et al. Neuroblastoma. Nat Rev Dis Primers. 2016;2(1):16078. https://doi.org/10.1038/nrdp.2016.78.
Pearson AD, Pinkerton CR, Lewis IJ, Imeson J, Ellershaw C, Machin D. High-dose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: a randomised trial. Lancet Oncol. 2008;9(3):247–56. https://doi.org/10.1016/S1470-2045(08)70069-X.
Holmes K, Pötschger U, Pearson ADJ, Sarnacki S, Cecchetto G, Gomez-Chacon J et al. Influence of surgical excision on the survival of patients with stage 4 high-risk neuroblastoma: a report from the HR-NBL1/SIOPEN study. J Clin Oncol. 2020;38(25):2902–15. https://doi.org/10.1200/JCO.19.03117.
Ladenstein R, Pötschger U, Pearson ADJ, Brock P, Luksch R, Castel V, et al. Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN): an international, randomised, multi-arm, open-label, phase 3 trial. Lancet Oncol. 2017;18(4):500–14. https://doi.org/10.1016/S1470-2045(17)30070-0.
Arumugam S, Manning-Cork NJ, Gains JE, Boterberg T, Gaze MN. The evidence for external beam radiotherapy in high-risk neuroblastoma of childhood: a systematic review. Clin Oncol (R Coll Radiol). 2019;31(3):182–90. https://doi.org/10.1016/j.clon.2018.11.031.
Ladenstein R, Pötschger U, Valteau-Couanet D, Luksch R, Castel V, Ash S et al. Investigation of the role of dinutuximab beta-based immunotherapy in the SIOPEN High-Risk Neuroblastoma 1 trial (HR-NBL1). Cancers (Basel). 2020;12(2):309. https://doi.org/10.3390/cancers12020309.
Mairs RJ, Gaze MN, Barrett A. The uptake and retention of metaiodobenzyl guanidine by the neuroblastoma cell line NB1-G. Br J Cancer. 1991;64(2):293–5. https://doi.org/10.1038/bjc.1991.294.
Wilson JS, Gains JE, Moroz V, Wheatley K, Gaze MN. A systematic review of 131I-meta iodobenzylguanidine molecular radiotherapy for neuroblastoma. Eur J Cancer. 2014;50(4):801–15. https://doi.org/10.1016/j.ejca.2013.11.016.
Berthold F, Spix C, Kaatsch P, Lampert F. Incidence, survival, and treatment of localized and metastatic neuroblastoma in Germany 1979-2015. Paediatr Drugs. 2017;19(6):577–93. https://doi.org/10.1007/s40272-017-0251-3.
Pinto NR, Applebaum MA, Volchenboum SL, Matthay KK, London WB, Ambros PF, et al. Advances in risk classification and treatment strategies for neuroblastoma. J Clin Oncol. 2015;33(27):3008–17. https://doi.org/10.1200/JCO.2014.59.4648.
Park JR, Kreissman SG, London WB, Naranjo A, Cohn SL, Hogarty MD, et al. Effect of tandem autologous stem cell transplant vs single transplant on event-free survival in patients with high-risk neuroblastoma: a randomized clinical trial. JAMA. 2019;322(8):746–55. https://doi.org/10.1001/jama.2019.11642.
Gaze MN, Gains JE, Walker C, Bomanji JB. Optimization of molecular radiotherapy with [131I]-meta iodobenzylguanidine for high-risk neuroblastoma. Q J Nucl Med Mol Imaging. 2013;57(1):66–78.
Mairs RJ, Boyd M. Preclinical assessment of strategies for enhancement of metaiodobenzylguanidine therapy of neuroendocrine tumors. Semin Nucl Med. 2011;41(5):334–44. https://doi.org/10.1053/j.semnuclmed.2011.03.004.
Warburg O. The metabolism of tumours: Arnold Constable London, UK; 1930.
Zhao Y, Butler EB, Tan M. Targeting cellular metabolism to improve cancer therapeutics. Cell Death Dis. 2013;4(3):e532. https://doi.org/10.1038/cddis.2013.60.
El Mjiyad N, Caro-Maldonado A, Ramirez-Peinado S, Munoz-Pinedo C. Sugar-free approaches to cancer cell killing. Oncogene. 2011;30(3):253–64. https://doi.org/10.1038/onc.2010.466.
Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012;18(20):5585–94. https://doi.org/10.1158/1078-0432.CCR-12-0858.
Slade RF, Hunt DA, Pochet MM, Venema VJ, Hennigar RA. Characterization and inhibition of fatty acid synthase in pediatric tumor cell lines. Anticancer Res. 2003;23(2B):1235–43.
Zirath H, Frenzel A, Oliynyk G, Segerstrom L, Westermark UK, Larsson K, et al. MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells. Proc Natl Acad Sci U S A. 2013;110(25):10258–63. https://doi.org/10.1073/pnas.1222404110.
Storz P. Reactive oxygen species in tumor progression. Front Biosci. 2005;10(2):1881–96. https://doi.org/10.2741/1667.
Lin X, Zhang F, Bradbury CM, Kaushal A, Li L, Spitz DR, et al. 2-Deoxy-D-glucose-induced cytotoxicity and radiosensitization in tumor cells is mediated via disruptions in thiol metabolism. Cancer Res. 2003;63(12):3413–7.
Raez LE, Papadopoulos K, Ricart AD, Chiorean EG, Dipaola RS, Stein MN, et al. A phase I dose-escalation trial of 2-deoxy-D-glucose alone or combined with docetaxel in patients with advanced solid tumors. Cancer Chemother Pharmacol. 2013;71(2):523–30. https://doi.org/10.1007/s00280-012-2045-1.
Shaw RJ, Lamia KA, Vasquez D, Koo SH, Bardeesy N, Depinho RA, et al. The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science. 2005;310(5754):1642–6. https://doi.org/10.1126/science.1120781.
El-Mir MY, Nogueira V, Fontaine E, Averet N, Rigoulet M, Leverve X. Dimethylbiguanide inhibits cell respiration via an indirect effect targeted on the respiratory chain complex I. J Biol Chem. 2000;275(1):223–8. https://doi.org/10.1074/jbc.275.1.223.
Owen MR, Doran E, Halestrap AP. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem J. 2000;348(Pt 3):607–14. https://doi.org/10.1042/bj3480607.
Pollak M. Potential applications for biguanides in oncology. J Clin Invest. 2013;123(9):3693–700. https://doi.org/10.1172/JCI67232.
Jiralerspong S, Palla SL, Giordano SH, Meric-Bernstam F, Liedtke C, Barnett CM, et al. Metformin and pathologic complete responses to neoadjuvant chemotherapy in diabetic patients with breast cancer. J Clin Oncol. 2009;27(20):3297–302. https://doi.org/10.1200/JCO.2009.19.6410.
Libby G, Donnelly LA, Donnan PT, Alessi DR, Morris AD, Evans JM. New users of metformin are at low risk of incident cancer: a cohort study among people with type 2 diabetes. Diabetes Care. 2009;32(9):1620–5. https://doi.org/10.2337/dc08-2175.
Margel D, Urbach DR, Lipscombe LL, Bell CM, Kulkarni G, Austin PC, et al. Metformin use and all-cause and prostate cancer-specific mortality among men with diabetes. J Clin Oncol. 2013;31(25):3069–75. https://doi.org/10.1200/JCO.2012.46.7043.
Fasih A, Elbaz HA, Huttemann M, Konski AA, Zielske SP. Radiosensitization of pancreatic cancer cells by metformin through the AMPK pathway. Radiat Res. 2014;182(1):50–9. https://doi.org/10.1667/RR13568.1.
Liu J, Hou M, Yuan T, Yi G, Zhang S, Shao X, et al. Enhanced cytotoxic effect of low doses of metformin combined with ionizing radiation on hepatoma cells via ATP deprivation and inhibition of DNA repair. Oncol Rep. 2012;28(4):1406–12. https://doi.org/10.3892/or.2012.1932.
Singh D, Banerji AK, Dwarakanath BS, Tripathi RP, Gupta JP, Mathew TL, et al. Optimizing cancer radiotherapy with 2-deoxy-D-glucose dose escalation studies in patients with glioblastoma multiforme. Strahlenther Onkol. 2005;181(8):507–14. https://doi.org/10.1007/s00066-005-1320-z.
Zhang Y, Storr SJ, Johnson K, Green AR, Rakha EA, Ellis IO, et al. Involvement of metformin and AMPK in the radioresponse and prognosis of luminal versus basal-like breast cancer treated with radiotherapy. Oncotarget. 2014;5(24):12936–49. https://doi.org/10.18632/oncotarget.2683.
Chuang JH, Chou MH, Tai MH, Lin TK, Liou CW, Chen T, et al. 2-Deoxyglucose treatment complements the cisplatin- or BH3-only mimetic-induced suppression of neuroblastoma cell growth. Int J Biochem Cell Biol. 2013;45(5):944–51. https://doi.org/10.1016/j.biocel.2013.01.019.
Esteva FJ, Moulder SL, Gonzalez-Angulo AM, Ensor J, Murray JL, Green MC, et al. Phase I trial of exemestane in combination with metformin and rosiglitazone in nondiabetic obese postmenopausal women with hormone receptor-positive metastatic breast cancer. Cancer Chemother Pharmacol. 2013;71(1):63–72. https://doi.org/10.1007/s00280-012-1977-9.
Boyd M, Cunningham SH, Brown MM, Mairs RJ, Wheldon TE. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine. Gene Ther. 1999;6(6):1147–52. https://doi.org/10.1038/sj.gt.3300905.
Nile DL, Rae C, Hyndman IJ, Gaze MN, Mairs RJ. An evaluation in vitro of PARP-1 inhibitors, rucaparib and olaparib, as radiosensitisers for the treatment of neuroblastoma. BMC Cancer. 2016;16(1):621. https://doi.org/10.1186/s12885-016-2656-8.
Rae C, Haberkorn U, Babich JW, Mairs RJ. Inhibition of fatty acid synthase sensitizes prostate cancer cells to radiotherapy. Radiat Res. 2015;184(5):482–93. https://doi.org/10.1667/RR14173.1.
Tesson M, Vasan R, Hock A, Nixon C, Rae C, Gaze M, et al. An evaluation in vitro of the efficacy of nutlin-3 and topotecan in combination with (177)Lu-DOTATATE for the treatment of neuroblastoma. Oncotarget. 2018;9(49):29082–96. https://doi.org/10.18632/oncotarget.25607.
Neshasteh-Riz A, Angerson WJ, Reeves JR, Smith G, Rampling R, Mairs RJ. Incorporation of iododeoxyuridine in multicellular glioma spheroids: implications for DNA-targeted radiotherapy using Auger electron emitters. Br J Cancer. 1997;75(4):493–9. https://doi.org/10.1038/bjc.1997.86.
Tautenhahn R, Bottcher C, Neumann S. Highly sensitive feature detection for high resolution LC/MS. BMC Bioinformatics. 2008;9(1):504. https://doi.org/10.1186/1471-2105-9-504.
Scheltema RA, Jankevics A, Jansen RC, Swertz MA, Breitling R. PeakML/mzMatch: a file format, Java library, R library, and tool-chain for mass spectrometry data analysis. Anal Chem. 2011;83(7):2786–93. https://doi.org/10.1021/ac2000994.
Gloaguen Y, Morton F, Daly R, Gurden R, Rogers S, Wandy J, et al. PiMP my metabolome: an integrated, web-based tool for LC-MS metabolomics data. Bioinformatics. 2017;33(24):4007–9. https://doi.org/10.1093/bioinformatics/btx499.
Vande Voorde J, Ackermann T, Pfetzer N, Sumpton D, Mackay G, Kalna G, et al. Improving the metabolic fidelity of cancer models with a physiological cell culture medium. Sci Adv. 2019;5(1):eaau7314.
Nile DL, Brown AE, Kumaheri MA, Blair HR, Heggie A, Miwa S, et al. Age-related mitochondrial DNA depletion and the impact on pancreatic Beta cell function. Plos One. 2014;9(12):e115433. https://doi.org/10.1371/journal.pone.0115433.
Ben Sahra I, Laurent K, Giuliano S, Larbret F, Ponzio G, Gounon P, et al. Targeting cancer cell metabolism: the combination of metformin and 2-deoxyglucose induces p53-dependent apoptosis in prostate cancer cells. Cancer Res. 2010;70(6):2465–75. https://doi.org/10.1158/0008-5472.CAN-09-2782.
Bizjak M, Malavasic P, Dolinar K, Pohar J, Pirkmajer S, Pavlin M. Combined treatment with metformin and 2-deoxy glucose induces detachment of viable MDA-MB-231 breast cancer cells in vitro. Sci Rep. 2017;7(1):1761. https://doi.org/10.1038/s41598-017-01801-5.
Levesley J, Steele L, Taylor C, Sinha P, Lawler SE. ABT-263 enhances sensitivity to metformin and 2-deoxyglucose in pediatric glioma by promoting apoptotic cell death. Plos One. 2013;8(5):e64051. https://doi.org/10.1371/journal.pone.0064051.
Chatterjee S, Thaker N, De A. Combined 2-deoxy glucose and metformin improves therapeutic efficacy of sodium-iodide symporter-mediated targeted radioiodine therapy in breast cancer cells. Breast Cancer (Dove Med Press). 2015;7:251–65.
McCluskey AG, Mairs RJ, Tesson M, Pimlott SL, Babich JW, Gaze MN, et al. Inhibition of poly(ADP-Ribose) polymerase enhances the toxicity of 131I-metaiodobenzylguanidine/topotecan combination therapy to cells and xenografts that express the noradrenaline transporter. J Nucl Med. 2012;53(7):1146–54. https://doi.org/10.2967/jnumed.111.095943.
Pawlik TM, Keyomarsi K. Role of cell cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol Biol Phys. 2004;59(4):928–42. https://doi.org/10.1016/j.ijrobp.2004.03.005.
Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, et al. Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma. J Clin Oncol. 2007;25(9):1054–60. https://doi.org/10.1200/JCO.2006.09.3484.
Ruiz-Perez MV, Medina MA, Urdiales JL, Keinanen TA, Sanchez-Jimenez F. Polyamine metabolism is sensitive to glycolysis inhibition in human neuroblastoma cells. J Biol Chem. 2015;290(10):6106–19. https://doi.org/10.1074/jbc.M114.619197.
Tweddle DA, Malcolm AJ, Bown N, Pearson AD, Lunec J. Evidence for the development of p53 mutations after cytotoxic therapy in a neuroblastoma cell line. Cancer Res. 2001;61(1):8–13.
Keshelava N, Seeger RC, Groshen S, Reynolds CP. Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. Cancer Res. 1998;58(23):5396–405.
Brodeur GM, Seeger RC, Schwab M, Varmus HE, Bishop JM. Amplification of N-myc in untreated human neuroblastomas correlates with advanced disease stage. Science. 1984;224(4653):1121–4. https://doi.org/10.1126/science.6719137.
Dier U, Shin DH, Hemachandra LP, Uusitalo LM, Hempel N. Bioenergetic analysis of ovarian cancer cell lines: profiling of histological subtypes and identification of a mitochondria-defective cell line. Plos One. 2014;9(5):e98479. https://doi.org/10.1371/journal.pone.0098479.
Xi H, Kurtoglu M, Lampidis TJ. The wonders of 2-deoxy-D-glucose. IUBMB Life. 2014;66(2):110–21. https://doi.org/10.1002/iub.1251.
Aird KM, Zhang R. Nucleotide metabolism, oncogene-induced senescence and cancer. Cancer Lett. 2015;356(2 Pt A):204–10.
The authors would thank Lucie de Beauchamp and David Strachan for their help and assistance with the Seahorse Analyser and the IncuCyte Imaging System, respectively.
This work was funded by Children with Cancer UK (grant numbers 15-191 and 17-243) and a Wellcome Institutional Strategic Support Fund (ISSF) Feasibility Award. Dr. Mark N. Gaze is supported by the National Institute for Health Research University College London Hospitals Biomedical Research Centre and by the Radiation Research Unit at the Cancer Research UK City of London Centre Award (C7893/A28990).
Ethics approval and consent to participate
Consent for publication
All authors consent to the publication of data reported in this manuscript.
The authors declare that they have no competing interests.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
. The effect of 2-DG and metformin on cell survival. Supplementary Figure S2. The radiosensitising effect of 2-DG and metformin as single agents. Supplementary Figure S3. The effect of combination treatment on glycolytic and mitochondrial metabolites. Supplementary Figure S4. Effects of 2-DG treatment on purine metabolism. Supplementary Figure S5. Effects of 2-DG treatment on pyrimidine metabolism. Supplementary Figure S6. The effect of combination treatment on mitochondrial respiration, glycolysis and cellular energy production. Supplementary Figure S7. The effect of combination treatment on mitochondrial respiration, glycolysis and cellular energy production. Supplementary Figure S8. The effect of 2-DG and metformin on the cell cycle. Supplementary Figure S9. The effect of combination treatment on apoptotic frequency.
About this article
Cite this article
Nile, D.L., Rae, C., Walker, D.J. et al. Inhibition of glycolysis and mitochondrial respiration promotes radiosensitisation of neuroblastoma and glioma cells. Cancer Metab 9, 24 (2021). https://doi.org/10.1186/s40170-021-00258-5